Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial

Table 4 Correlation between changes in the E/e’ ratio and each clinical parameter in the ipragliflozin group stratified by baseline BMI

Factors	Patients with a BMI < 25 kg/m² (n = 9)		Patients with a BMI ≥ 25 kg/m² (n = 19)
	Correlation coefficient	P-value	Correlation coefficient	P-value
Systolic blood pressure (mmHg)	0.276	0.472	0.357	0.133
Diastolic blood pressure (mmHg)	0.288	0.452	0.507	0.027
BMI (kg/m²)	0.234	0.544	0.123	0.616
Haemoglobin (g/dL)	0.151	0.699	− 0.162	0.506
P-III-P (ng/mL)	− 0.300	0.437	− 0.030	0.905
UACR (mg/g Cre)	0.524	0.197	0.279	0.247
LAVi (mL/m²)	− 0.033	0.948	0.004	0.986
RHI	− 0.283	0.463	− 0.292	0.225

Data are expressed as the median (interquartile range [IQR]), Spearman's rank correlation coefficient, and P-value for test whether the correlation coefficient is 0
BMI, body mass index; E/e’, maximum early diastolic velocity to average early diastolic peak velocity; LAVi, left atrial volume index; P-III-P; procollagen III peptide; RHI, reactive hyperaemia index; UACR, urine albumin-to-creatinine ratio

ISSN: 1475-2840